Monitor for FDA advisory committee briefing documents and potential label discussions ahead of the Q1 2027 PDUFA date. The strong Phase 3 data de-risks approval, but the binary regulatory event remains the key catalyst. Watch for any safety signals or manufacturing issues in the review process. The EMA review adds a second major regulatory catalyst.
Price Chart
Executive Summary
Takeda announced FDA Priority Review acceptance of its NDA for zasocitinib (TAK-279) in moderate-to-severe plaque psoriasis, with a PDUFA target in Q1 2027. Phase 3 data showed strong efficacy across endpoints (e.g., ~70% sPGA 0/1 at week 16) with a clean safety profile, positioning it as a potential best-in-class oral TYK2 inhibitor. The EMA also accepted the MAA, and the filing has no impact on FY2027 guidance, making this a significant pipeline catalyst but with binary regulatory risk ahead.
Key Facts
- FDA accepted NDA under Priority Review for zasocitinib (TAK-279) in moderate-to-severe plaque psoriasis.
- PDUFA target action date is Q1 2027.
- Phase 3 LATITUDE PsO 3001/3002 studies met all co-primary and 44 ranked secondary endpoints (p<0.001).
- At week 16, 71% (3001) and 69% (3002) of zasocitinib patients achieved sPGA 0/1 vs 11%/13% placebo.
- PASI 75 at week 16: 76% (3001) and 71% (3002) vs 12% placebo.
- PASI 100 at week 16: 33% (3001) and 25% (3002) vs <1% placebo.
- EMA also accepted the MAA for zasocitinib in plaque psoriasis.
- No new safety signals; most common AEs were URTI (10.1%), nasopharyngitis (6.2%), and acne (6.5%).
- NDA filing has no significant impact on FY2027 consolidated financial forecast.
- Takeda is also evaluating zasocitinib in Phase 3 psoriatic arthritis and Phase 2 Crohn's, UC, vitiligo, and hidradenitis suppurativa.
Financial Impact
Pipeline catalyst with blockbuster potential; zasocitinib could address a large psoriasis market (66.4M patients globally). No immediate revenue impact as drug is not yet approved.
Risk Factors
- Regulatory risk: FDA could issue a Complete Response Letter (CRL) or require additional data.
- Commercial risk: Competition from existing oral (apremilast, deucravacitinib) and biologic therapies.
- Execution risk: Manufacturing scale-up and launch execution for a potential blockbuster.
- Pricing and reimbursement risk in a competitive psoriasis market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001395064-26-000337 |
| Document: 0001395064-26-000337-index-headers.html | 0001395064-26-000337 |
| Document: 0001395064-26-000337-index.html | 0001395064-26-000337 |
| Document: 0001395064-26-000337.txt | 0001395064-26-000337 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $18.60 $18.89 | ▲ +1.56% | ▲ +1.45% | $17.86 (−3.98%) |
Aug 21, 2026 6w ago | Insider Cluster | $18.18 $18.03 | ▼ −0.83% | ▼ −1.30% | $17.86 (−1.76%) |
Aug 19, 2026 6w ago | Insider Cluster | $18.34 $18.23 | ▼ −0.60% | ▼ −0.21% | $17.86 (−2.62%) |
Aug 14, 2026 7w ago | Court Ruling | $17.63 $18.18 | ▲ +3.12% | ▲ +4.49% | $17.86 (+1.30%) |
Aug 13, 2026 7w ago | Insider Cluster | $17.39 $18.13 | ▲ +4.26% | ▲ +6.22% | $17.86 (+2.70%) |
Aug 13, 2026 7w ago | Insider Cluster | $17.39 $18.13 | ▲ +4.26% | ▲ +6.22% | $17.86 (+2.70%) |
Jul 9, 2026 12w ago | 6-K | $16.61 $16.73 | ▲ +0.72% | ▲ +0.85% | $17.86 (+7.53%) |
Jul 8, 2026 12w ago | 6-K | $16.75 $16.39 | ▼ −2.15% | ▼ −3.01% | $17.86 (+6.63%) |
Jul 6, 2026 12w ago | 3 | $16.89 $16.56 | ▼ −1.95% | ▼ −2.44% | $17.86 (+5.74%) |
Jun 29, 2026 13w ago | 6-K | $15.98 $16.89 | ▲ +5.69% | ▲ +4.31% | $17.86 (+11.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access